Oxidative and nitrative stress CD36, a class B scavenger receptor present in microglia, endothelium and leukocytes, plays a key role in ischemic brain injury by promoting the expression of inflammatory genes and production of reactive oxygen species (ROS). However, it is not known whether ischemic brain damage is mediated by CD36 activation in resident brain cells, i.e., microglia, or by blood-borne cells that infiltrate the brain. To address this question, we studied oxygen-glucose deprivation (OGD) in hippocampal slice cultures, a model of ischemic injury that does not involve cells extrinsic to the brain. We found that CD36 gene knockout does not afford protection of hippocampal slices to OGD-induced cytotoxicity. In contrast, immunoactivated bone marrow-derived monocytes-macrophages (BMM) from wild type (WT) mice trigger hippocampal damage when incubated with brain slices via a mechanism that is prevented in CD36−/− BMM. The neurotoxic activity of CD36+/+ BMM was attributed to reactive oxygen species (ROS) since it was concomitant with increased ROS production and could be prevented by treatment with a selective ROS scavenger, MnTBAP, or a peroxynitrite decomposition catalyst, FeTPPS. Importantly, ROS production and accumulation 3-nitrotyrosine in hippocampal proteins (a hallmark of peroxynitrite production) was significantly dampened in immunoactivated CD36−/− BMM, whereas production of NO-derived metabolites (nitrite and nitrate) was unaltered. We conclude that CD36 signaling may not contribute to injury induced by OGD in the brain itself but is involved in the neurotoxicity mediated by activated BMM. These findings are consistent with the hypothesis that CD36 in infiltrating inflammatory cells drives peroxynitrite-mediated ischemic brain damage. Accordingly, targeting CD36 in the vascular compartment may protect against neurotoxicity in the ischemic brain.
Introduction
Ischemic brain injury results from the concerted action of multiple pathogenic factors acting in a well-defined temporal sequence (Moskowitz et al., 2010) . Whereas energy failure, glutamate and Ca 2+ dysregulation mediate the early phase of the injury, activation of inflammatory pathways contributes to the expansion of the damage in the late stages of the ischemic cascade (Moskowitz et al., 2010) . After cerebral ischemia, cytokines, adhesion molecules and chemokines lead to influx of circulating leukocytes into the brain and activation of resident inflammatory cells, which contribute to the damage (Iadecola, 2004) . In experimental animals, inhibition of post-ischemic inflammation ameliorates ischemic injury with an extended time widow (Wang et al., 2007; Iadecola et al., 2004) , but initial attempts to treat stroke patients using similar approaches have not been successful (Sughrue et al., 2004) . This failure reflects, in part, our incomplete understanding of the biological processes underlying post-ischemic inflammatory signaling (Furuya et al., 2001; Sughrue et al., 2004; Lakhan et al., 2009; Hallenbeck et al., 2006) . In particular, the relative roles that infiltrating blood-borne cells and resident brain cells play in the mechanisms of the injury remain to be elucidated.
The scavenger receptor CD36 has emerged as a key factor in postischemic inflammatory signaling. CD36, expressed in monocytesmacrophages, endothelial cells and microglia, recognizes a wide variety of ligands, like modified lipids, β-amyloid, apoptotic cells, and anti-angiogenic factor thrombospondin-1 (Silverstein and Febbraio, 2009 ). CD36, acting in concert with other scavenger receptors and toll-like receptors, may recognize molecular patterns that are generated by cellular damage (Akashi-Takamura and Miyake, 2008) and trigger adaptive cellular responses, including production of reactive oxygen species (ROS) and expression of proinflammatory Neurobiology of Disease 42 (2011) 292-299 
